 |
6 Diseases |  |
125 Trials |
|
125 Trials |  |
2571 News |  |
| «12...1112131415161718192021...3334» |
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Multi-institutional analysis of real-world activity and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_294;
Clinicopathological characteristics, Overall Response Rate (ORR) and Disease Control Rate (DCR), Overall Survival (OS) and Progression-Free Survival (PFS) and safety data were retrospectively collected and analyzed. Conclusions Our series provides further evidence on the activity and safety of TAS102 plus BEV combination in a real-world series of Western refractory mCRC patients.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Muscle quantity and quality in metastatic colorectal cancer patients during third-line therapy with regorafenib or TAS102 () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_286;
MML appeared more in patients receiving Regorafenib, although this wasn't statistically significant. These results must be interpreted with caution in consideration of the limited sample size.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_263;
Conclusions Biweekly administration of trifluridine/tipiracil, irinotecan, plus bevacizumab may decrease febrile neutropenia with moderate antitumor activity in previously treated mCRC patients. Further investigation of this combination therapy is required.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Precision oncology without biomarkers: Assessing drug sensitivity in patient-derived tumoroids to guide mCRC 3rd line therapy () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_248;
These tumoroids were added to pre-loaded gel arrays containing the drugs of interest (FOLFOX, FOLFIRI, FOLFOXIRI, regorafenib, trifluridine + tipiracil, mitomycin C + 5FU, gemcitabine + 5FU, temozolomide + irinotecan)...Conclusions IndiTreat® provides an individual drug sensitivity profile that clearly differentiated between "low sensitivity" and "high sensitivity" tumoroids for each drug in the panel. This information can be used by oncologists to determine if any of the treatments indicated in guidelines can be an option for that patient, or if she might benefit from the off-label use of certain drugs, thus expanding their treatment options and achieving the benefits of personalization even with standard chemotherapy regimens.
- Opdivo (nivolumab) / Ono Pharma, BMS
Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_230;
The survival of patients who received the best supportive care (cohort A) was compared to those included in the main study (cohort B). Conclusions Salvage chemotherapy as much as possible after NIVO therapy could improve the AGC prognosis.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Efficacy and safety data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Real-world data from the non-interventional TACTIC study () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_224;
P=N/A
Independent of other baseline characteristics such as ECOG PS and age, low metastatic burden and indolent disease were factors of good prognosis with regards of OS and PFS. [1]Mayer et al,NEnglJMed2015 [2]Tabernero et al,ESMOOpen2020.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
RETRO-TAS, a retrospective observational study of rifluridine/tipiracil in chemorefractory metastatic colorectal cancer () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_219;
P=N/A
Prognostic factors were evaluated by Cox regression model and Kaplan-Meier curves, along with log-rank tests using Stata/MP 16.0 for Windows. Conclusions This real-world observational study confirms and adds on the findings of the RECOURSE phase III study in relation to the toxicity and the effectiveness of TAS-102 in all subgroups of patients with chemotherapy refractory mCRC, regardless of mutational status and sidedness.
- Tecentriq (atezolizumab) / Roche, Reolysin (pelareorep) / Oncolytics, Andrus Reo
GOBLET: A phase 1/2 multiple indication signal finding and biomarker study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – safety and preliminary response results () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_218;
This is consistent with the favorable safety profile observed in prior studies of pela in multiple cancer indications, and it supports the ability to safely treat patients with advanced GI cancers using pela in combination with checkpoint inhibitors and chemotherapy. Preliminary tumor responses to therapy in first-line pancreatic cancer patients are encouraging.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and TAS-102 in the treatment of relapsed/refractory metastatic colorectal cancer () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_214;
Results also suggest that rego 80+ delays disease progression in comparison. With its more favorable safety profile, rego 80+ should be considered a preferred option for optimizing clinical outcomes in patients with relapsed/refractory mCRC.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Does the chemotherapeutic efficacy of trifluridine/tipiracil plus bevacizumab change depend on pre-treatment vascular endothelial growth factor inhibitors? () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_204;
Subgroup analyses of prognostic and predictive efficacy markers were performed. Conclusions Chemotherapeutic efficacy and safety of FTD/TPIplus BEV did not differ regardless of the pre treatment VEGF inhibitors.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophagogastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas) (Auditorium B; Level 0) - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_168;
Compared to the heavily pretreated patients in TAGS, only 42% of patients in LonGas had received at least 2 lines of therapy. This may account for the unexpected long PFS in patients receiving FTD/TPI monotherapy.
- Discussant: O-3, O-4, SO-7, SO-8 (Auditorium B; Level 0) - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_162;
This may account for the unexpected long PFS in patients receiving FTD/TPI monotherapy. Learning Objectives: O-3: Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): expanded efficacy and safety analyses from CheckMate 648 - Ian Chau, et al O-4: Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophagogastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas) - Per Pfeiffer, et al SO-7: Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial - Yelena Janjigian, et al SO-8: Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR) - Hisato Kawakami, et al
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
Discussant: SO-18, SO-19, SO-20, SO-21 (Auditorium B; Level 0) - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_42;
Learning Objectives: O-3: Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): expanded efficacy and safety analyses from CheckMate 648 - Ian Chau, et al O-4: Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophagogastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas) - Per Pfeiffer, et al SO-7: Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial - Yelena Janjigian, et al SO-8: Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR) - Hisato Kawakami, et al Learning Objectives: SO-18: Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: pooled analysis of PRECONNECT and TALLISUR studies - Lucjan Wyrwicz, et al SO-19: Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer - Hiroya Taniguchi, et al SO-20: Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial - Christophe Borg, et al SO-21: Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: an individual patient data pooled analysis of clinical trials - Alessandra Raimondi, et al
- || ASP1570 / Astellas
Trial completion date, Trial primary completion date, Monotherapy: KEYNOTE-E59: A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors (clinicaltrials.gov) - May 8, 2022
P1, N=138, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Learning Objectives: SO-18: Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: pooled analysis of PRECONNECT and TALLISUR studies - Lucjan Wyrwicz, et al SO-19: Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer - Hiroya Taniguchi, et al SO-20: Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial - Christophe Borg, et al SO-21: Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: an individual patient data pooled analysis of clinical trials - Alessandra Raimondi, et al Trial completion date: May 2024 --> Jul 2026 | Trial primary completion date: May 2024 --> Jul 2026
- |||| Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer, Lumakras (sotorasib) / Amgen
Enrollment open: CodeBreak 300: Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (clinicaltrials.gov) - May 8, 2022
P3, N=153, Recruiting, Sponsor: Amgen
Trial completion date: May 2024 --> Jul 2026 | Trial primary completion date: May 2024 --> Jul 2026 Not yet recruiting --> Recruiting
- || Vectibix (panitumumab) / Amgen, Takeda
Clinical, P2 data, Review, Journal: Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09. (Pubmed Central) - May 6, 2022
Not yet recruiting --> Recruiting Irinotecan plus panitumumab rechallenge is a promising third-line treatment regimen in patients with metastatic wild-type KRAS colorectal cancer.
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study (clinicaltrials.gov) - May 6, 2022
P2, N=41, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Irinotecan plus panitumumab rechallenge is a promising third-line treatment regimen in patients with metastatic wild-type KRAS colorectal cancer. Recruiting --> Active, not recruiting
- |||||| Opdualag (nivolumab/relatlimab-rmbw) / BMS, Opdivo (nivolumab) / BMS
Enrollment open: RELATIVITY-123: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (clinicaltrials.gov) - May 6, 2022
P3, N=700, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer (clinicaltrials.gov) - May 6, 2022
P2, N=20, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Tukysa (tucatinib) / Pfizer
New P2 trial, Metastases: ACCRU-GI-2003: Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study (clinicaltrials.gov) - May 1, 2022
P2, N=30, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Study protocol of an open-label, single-arm, phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC). (Available On Demand; 153b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2012;
P2
Gemcitabine/Cisplatin has been the standard of care in the first-line therapy of BTC for a decade...Currently, 3 out of the planned 6 German study sites are opened for recruitment and 6 patients have been enrolled. The primary study endpoint is estimated to be evaluated in 2023.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Clinical characteristics, outcomes and survival of patients with metastatic colorectal cancer on phase I trials: A single center experience from 1999 to 2022. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1539;
Our experience sheds light on the potential for improved outcomes in terms of survival. The survival of patients is at par with those used in late-stage disease including regorafenib and trifluridine/tipiracil.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Neutropenia as a predictor of efficacy in the treatment of metastatic colorectal cancer with TAS-102 (trifluridine - tipiracil). () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1474;
In our study we obtain similar results, with better OS results for patients with grade 3-4 neutropenia. Therefore, we consider severe neutropenia as a possible predictor of the efficacy of TAS-102.
- Chromosome 20q and 13q gain in metastatic colorectal cancer: Prognostic significance and genomic correlates. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1472;
The data indicate that 13q/20q gain and associated molecular signature are important prognostic markers in CRC.*First-line regimens were primarily a combination of fluorouracil, leucovorin, or capecitabine, plus oxaliplatin or irinotecan (FOLFOX, CapeOx, FOLFIRI, FOLFOXIRI), with or without bevacizumab. Second-line regimens included first-line regimens not used as yet, or cetuximab or panitumumab.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Mekinist (trametinib) / Novartis
A phase I clinical trial of trametinib in combination with TAS-102 in patients with chemotherapy-resistant RAS-mutated (PIK3CA/PTEN-wild type) metastatic colorectal cancer. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1470;
P1
Trametinib in combination with TAS-102 demonstrated a manageable safety profile however did not achieve meaningful clinical benefit in patients with RAS-MT and PIK3CA / PTEN-WT refractory mCRC. Research sponsor: Novartis.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Codon-specific KRAS mutations predict overall survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. (Available On Demand; 387) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1394;
Together, KRASG12 mutations were associated with reduced OS benefit of FTD/TPI treatment, with potential implications for ̃28% of patients with metastatic colorectal cancer now considered for treatment with FTD/TPI. Furthermore, our data show that genomics-based precision medicine may be possible for a subset of chemotherapies.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer. (Available On Demand; 378) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1385;
Our pts treated with TAS-102 had comparable median PFS to the RECOURSE cohort but with significantly better OS as more than half continued to receive treatment. Biweekly dosing of TAS-102 with or without bevacizumab is well tolerated with significantly lower rates of Grade 3 neutropenia compared to the published data in the literature.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
FORECAST-1: Feasibility of organoid response assessment to define effective treatments for patients with colorectal cancer after failure of standard therapy. (Available On Demand; 377) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1384;
Two-thirds of patients achieved PDTO establishment to allow drug sensitivity testing in a timely manner. Of these further potentially efficacious treatments were able to be successfully identified.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer (mCRC): Results of a meta-analysis. (Available On Demand; 362) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1369;
P3
Limitations of the analysis include study design heterogeneity. Data from RCTs (eg, phase 3 SUNLIGHT trial [NCT04737187]) are required to confirm these findings.
- Baize'an (tislelizumab) / BeiGene, Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study. (Available On Demand; 360) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1367;
P2
Background: For adequately treated patients (pts) with advanced colorectal cancer, the current third-line treatment standard of TKIs or TAS-102 administration has a low clinical objective response rate and its effectiveness seems to be limited. Tislelizumab plus cetuximab and irinotecan shows an encouraging clinical efficacy and tolerable safety in previously treated pts with RAS wide-type advanced colorectal cancer.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC). (Available On Demand; 353) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1360;
With an improved toxicity profile, this alternative TAS -102 dosing schedule may be a more favorable option for future combination studies. Additional prospective data are needed to validate these findings.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Journal: Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS-102 plus bevacizumab. (Pubmed Central) - Apr 26, 2022
The median PFS and median OS were 4.4 and 14.9 months, respectively. In conclusion, prophylactic pegfilgrastim may facilitate the management of severe neutropenia without dose delays in patients with mCRC treated with TAS-102 plus bevacizumab.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
New P2 trial, Minimal residual disease, Circulating tumor DNA: TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (clinicaltrials.gov) - Apr 25, 2022
P2, N=15, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Stivarga (regorafenib) / Bayer
Retrospective data, Journal: Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. (Pubmed Central) - Apr 22, 2022
The early modulation of circulating Ang-2 predicts the efficacy of regorafenib. Baseline Ang-2 plasma levels are an independent prognostic biomarker in chemorefractory metastatic colorectal cancer.
- ||| Tirazone (tirapazamine) / Teclison, SRI International
Enrollment change, Trial completion date, Trial primary completion date, Metastases: KEYNOTE-A91: TATE and Pembrolizumab (MK3475) in mCRC and NSCLC (clinicaltrials.gov) - Apr 21, 2022
P2, N=110, Recruiting, Sponsor: Teclison Ltd.
Baseline Ang-2 plasma levels are an independent prognostic biomarker in chemorefractory metastatic colorectal cancer. N=60 --> 110 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Oct 2024
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Clinical, Journal: Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer: from clinical trials to daily clinical practice. (Pubmed Central) - Apr 20, 2022
N=60 --> 110 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Oct 2024 No abstract available
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, P3 data, Journal: Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). (Pubmed Central) - Apr 20, 2022
No abstract available The results of this subgroup analysis show the efficacy and tolerability of FTD/TPI treatment regardless of age in patients with mGC/GEJC who had received 2 or more prior treatments.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Journal: Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. (Pubmed Central) - Apr 19, 2022
Two patients (2.3%) had febrile neutropenia and there were no treatment-related deaths, where TAS-102 dose at treatment initiation was at clinician discretion.TRACC registry patients treated with TAS-102 were younger than those from the RECOURSE trial, with similar overall survival observed. Less strict application of RECIST criteria and less frequent imaging may have contributed to an apparently longer PFS.
- ||| Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion: Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients (clinicaltrials.gov) - Apr 19, 2022
P1, N=64, Completed, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Less strict application of RECIST criteria and less frequent imaging may have contributed to an apparently longer PFS. Recruiting --> Completed
- ||| murlentamab (GM102) / Exelixis
Trial completion, Enrollment change, Combination therapy, Metastases: Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers (clinicaltrials.gov) - Apr 14, 2022
P2a, N=65, Completed, Sponsor: GamaMabs Pharma
Recruiting --> Completed Active, not recruiting --> Completed | N=39 --> 65
- || Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) (clinicaltrials.gov) - Apr 14, 2022
P1, N=14, Active, not recruiting, Sponsor: Patrick Joseph Loehrer Sr.
Active, not recruiting --> Completed | N=39 --> 65 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> May 2025 | Trial primary completion date: Dec 2022 --> May 2021
- |||||||||| Opdualag (nivolumab/relatlimab-rmbw) / BMS, Opdivo (nivolumab) / BMS
New P3 trial: RELATIVITY-123: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 13, 2022
P3, N=700, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Clinical, Journal, Real-world evidence: Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population. (Pubmed Central) - Apr 9, 2022
In real-world Australian population, treatment choices differed based on KRAS status and will likely change with the availability of newer drugs on the pharmaceutical benefits scheme. Survival outcomes are comparable to newer agents in clinical trials for select patients.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Review, Journal: Trifluridine/tipiracil in the treatment of gastric cancer. (Pubmed Central) - Apr 6, 2022
Another phase 3 trial (TAGS) showed significant improvement of overall survival and progression-free survival in refractory gastric cancer and gastroesophageal junction cancer, leading to further approval from the FDA on February 2019, followed by Japan in August 2019 and the European Union in September 2019. As promising results have already been observed in the chemorefractory gastric and gastroesophageal-junction cancers, ongoing trials are assessing the use of trifluridine/tipiracil with other standard of care agents, aiming to further improve the survival rate of these patients.
- || Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Apr 6, 2022
P1, N=20, Active, not recruiting, Sponsor: University of California, Irvine
As promising results have already been observed in the chemorefractory gastric and gastroesophageal-junction cancers, ongoing trials are assessing the use of trifluridine/tipiracil with other standard of care agents, aiming to further improve the survival rate of these patients. Trial completion date: Sep 2022 --> Jan 2023 | Trial primary completion date: Mar 2022 --> Jul 2022 | Recruiting --> Active, not recruiting
- ||||| Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment closed, Combination therapy, Monotherapy, Metastases: SUNLIGHT: Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Apr 6, 2022
P3, N=490, Active, not recruiting, Sponsor: Taiho Oncology, Inc.
Trial completion date: Sep 2022 --> Jan 2023 | Trial primary completion date: Mar 2022 --> Jul 2022 | Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Tevimbra (tislelizumab-jsgr) / BeiGene, Avastin (bevacizumab) / Roche
New P2 trial: TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer (clinicaltrials.gov) - Apr 5, 2022
P2, N=25, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, capecitabine / Generic mfg.
Yes. I have used FLOX many times successfully in these circumstances. S1 is an oral fluoropyrimidine and may also cause Vasospasm as it is given continuously, as with UFT or capecitabine. TAS102 is not reported to do this. (Twitter) - Mar 29, 2022
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Journal, HEOR: Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastroesophageal junction, among patients previously treated in Greece. (Pubmed Central) - Mar 29, 2022
The total cost per patient was estimated to be €6,965 for FTD/TPI and €1,906 for BSC, while FTD/TPI was associated with 0.180 and 0.107 increments in LYs and QALYs, respectively, compared with BSC, resulting in an ICER of €47,144 per QALY gained and €28,112 per LY gained. The results indicated that FTD/TPI was estimated to be a cost-effective treatment option for eligible third line mGC patients, including GEJ, who have received at least two prior therapies for metastatic disease in Greece.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
There’s no S-1 in 🇺🇸. It’s more of a regulatory thing from what I understand. Correct me my colleagues if you know anything different? Also on trials, you can’t change ingredients if the cocktail. Method/dosing, yes. Also from a discussion standpoint, TAS-102? @HH_Oncodr (Twitter) - Mar 27, 2022